Retrospective analysis of cultured epidermal autografts in burn care
Ayelet Di Segni, Marina BenShoshan, Moti Harats, Nir Melnikov, Daniel Dothan, Helit Cohen, Rachel Kornhaber, Michelle Cleary, Erik Biros, Josef HaikObjective:
The study aimed to assess the effectiveness and safety of cultured epidermal autografts (CEAs) in treating severe burns. The authors hypothesised that the comprehensive method outlined would enhance patient outcomes by increasing treatment efficacy. It also highlighted the regulatory requirements for establishing a Good Manufacturing Practice infrastructure for cell therapy production in a hospital setting. The authors addressed the challenges of regulatory requirements, particularly in Israel, where the implementation was only possible via a clinical trial scheme.
Method:
Over five years, the authors conducted a study involving patients with burns covering an average of 67.5% of their total body surface area. The authors performed 45 transplantations, producing nearly 1000 grafts, equivalent to 3m 2 of skin, which were applied alone or in combination with traditional treatments. The comprehensive method for producing CEAs was assessed for reproducibility, efficacy and safety.
Results:
The experimental cohort comprised 13 patients with extensive burns. The manufacturing process proved reproducible and reliable, with no CEA-related infections or treatment-associated adverse events reported. CEAs were successfully applied either alone or in combination with conventional burn treatments. The combination of CEAs with Meek micrografts or meshed autografts was associated with improved graft take and accelerated wound closure. In addition, application of CEAs to donor sites was associated with enhanced wound healing and reduced pigmentation.
Conclusion:
This study demonstrates that the production and clinical application of CEAs can be safely and reproducibly implemented within a hospital-based Good Manufacturing Practice facility. CEAs represent a valuable adjunctive treatment for patients with extensive burns, particularly when combined with established autografting techniques. The favourable safety profile and clinical outcomes observed in this cohort support broader clinical adoption of this technology through appropriate regulatory pathways beyond the clinical trial setting.